Johnson & Johnson (JNJ) - News Mentions

Sign up to add (JNJ) to your portfolio and access more historical data.

00%
Est. daily news mentions.

Sign up to access historical data

Sign up

Similar companies

Company News Mentions
Eli Lilly and Company
Eli Lilly and Company
LLY		 1 50%
Pfizer
Pfizer
PFE		 3 81.3%
Astrazeneca
Astrazeneca
AZN		 0 100%
AbbVie
AbbVie
ABBV		 0 0%
TherapeuticsMD
TherapeuticsMD
TXMD		 0 0%
Wolfe Research Initiates Coverage of Johnson & Johnson (JNJ) with Outperform Recommendation
November 15
Johnson & Johnson stock underperforms Friday when compared to competitors despite daily gains
November 15
Johnson & Johnson (JNJ) Guggenheim Global Healthcare Conference (Transcript)
November 14
Johnson & Johnson MedTech announces partnership for soft tissue solutions
November 14
Johnson & Johnson : CHMP recommends RYBREVANT®▼ (amivantamab) in combination with LAZCLUZE®▼ (lazertinib) for the first line treatment of patients with EGFR mutated advanced non small cell lung cancer
November 14
Johnson & Johnson stock underperforms Thursday when compared to competitors
November 14
Why Is Johnson & Johnson (JNJ) Down 6.7% Since Last Earnings Report?
November 14
Johnson & Johnson : MedTech Announces Strategic Agreement with Responsive Arthroscopy to Expand Sports Soft Tissue Solutions
November 13
Johnson & Johnson sues Biden administration over payment terms for 340B hospitals
November 13
Greece as a center of innovation: Johnson & Johnson Innovative Medicine’s strategy for new treatments and clinical studies
November 13
Why Johnson & Johnson, Invitation Homes And Extra Space Storage Are Winners For Passive Income
November 13
Johnson & Johnson MedTech Receives IDE Approval for OTTAVA Robotic Surgical System
November 12
Johnson & Johnson: Tracking Well Above The Industry
November 12
Johnson & Johnson - Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjogren's disease
November 11
Johnson & Johnson : MedTech Receives IDE Approval for OTTAVA™ Robotic Surgical System
November 11
Johnson & Johnson's (NYSE:JNJ) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
November 10

Month over Month

Est. daily news mentions.

Oct 2024 1
Sep 2024 1
Aug 2024 1
Jul 2024 1
Jun 2024 1

How often is Johnson & Johnson mentioned in the news?

Johnson & Johnson was mentioned an estimated 0 times in online prominent news articles yesterday.

Analyzing News Mentions, how is Johnson & Johnson performing compared to its industry peers?

Johnson & Johnson underperforms its industry peers when it comes to News Mentions, ranking dead last.

Has there been an increase or decrease in news mentions of Johnson & Johnson in the last month?

There has been no significant change in the number of news mentions for Johnson & Johnson's compared to the last month.

Why is it important to track news mentions for Johnson & Johnson?

By monitoring mentions in the news for Johnson & Johnson, investors stay up to date on impactful events for the company, its industry and its competitors. Positive news might affect price in a positive way and negative news might affect price in a negative way. By tracking mentions over time, investors can also identify patterns, explore popularity and make informed decisions based on the evolving perception of Johnson & Johnson, ultimately improving their investment strategies.

Sign up and get more insights on Johnson & Johnson.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.

Top Stocks

Trending Stocks
Trending Stocks on WallStreetBets
Trending Stocks on Reddit
Top Stocks
Top Stock Performers Today
Bottom Stock Performers Today
Best Airlines Stocks
Best Bank Stocks
Best Semiconductor Stocks
Best Energy Stocks
Best Fintech Stocks
Best Robotics Stocks
Best Insurance Stocks

Our Data

Datasets
Stock alerts
AI Stock Picks
AI Stock Picks - Results
Fear & Greed Index
Meme Stocks
Threads Users
Stock Predictor
Stock Picking Reviews
Stock Trading Signals
House & Congress Trading
Earnings Calendar
Index

AltIndex

News
Pricing
Sign up
Log in
API
Journalist Access
Data Disclaimer
Contact